NCT05240612已完成1 期
A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Percentage of subjects with adverse reactions
研究概览
简要总结
The purposes of this study is to assess the safety, tolerability, and pharmacokinetics of MT-3921 in subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy(HAM).
Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Additional screening criteria check may apply for qualification:
- •Subjects aged 20 years or older on the day of consent
- •Subjects with a confirmed diagnosis of HAM according to the diagnostic algorithm of Practical Guideline for HAM 2019 on the day of consent
- •Subjects with an Osame's motor disability score (OMDS) of ≥4 and ≤6 at Screening and on the first day of the Treatment period (predose)
- •Subjects with no change in OMDS for at least 3 months before the day of consent
- •Subjects with a CSF concentration neopterin of ≥6 pmol/mL at Screening
- •Subjects on maintenance oral steroid therapy who have continued to receive the same dose equivalent to ≤10 mg/day of prednisolone for at least 3 months before the day of consent
排除标准
- •Additional screening criteria check may apply for qualification:
- •Subjects who have a history of anaphylaxis or clinically significant allergic reactions due to administration of antibody products
- •Subjects exhibiting or with a history of malignant tumor.
- •Subjects with adult T-cell leukemia/lymphoma (ATL) or those with positive HTLV-1 clonality test (Southern blot) at screening and suspected of having ATL
- •Subjects with spinal cord compression lesions, such as cervical spine disease, disc herniation, and ossification of the yellow ligament
- •Subjects with psychiatric disorders, epileptic seizures, or dementia.
- •Subjects with suicide attempts or suicidal ideation corresponding to item 4 or 5 on the Columbia Suicide Rating Scale (C-SSRS) at screening and/or on the first day of the Treatment period (predose)
- •Subjects exhibiting or with a history of hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection.
- •Subjects with the novel Coronavirus disease 2019 (COVID-19)
- •Subjects with severe illness
- •Male or female subjects of childbearing potential who do not agree to use a contraceptive measure from the day of consent to 16 weeks after the last dose of the investigational medical product
- •Female subjects who are pregnant, lactating, or may be pregnant
- •Subjects who have received anti-repulsive guidance molecule (RGM) a antibody containing this investigational medical product
- •Subjects who participated in other clinical studies (including clinical trials) and received drugs (including investigational medical products) or therapy within 12 weeks before the day of consent
结局指标
主要结局
Percentage of subjects with adverse reactions
时间窗: 36 weeks
Serum concentrations of MT-3921
时间窗: PK samples will be collected at predose, 1.5 hours, 2, 4, 8, 12, 20 (predose and 1.5 hours), 24, 36 weeks post-dose.
Percentage of subjects with adverse events
时间窗: 36 weeks
CSF concentrations of MT-3921
时间窗: PK samples will be collected at 2, 4, 12, 24 weeks post-dose.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjurySpinal Cord InjuryNCT04096950Mitsubishi Tanabe Pharma America Inc.3
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesHealthy Adult MalesNCT05396235Mitsubishi Tanabe Pharma Corporation10
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects with HAMHuman T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)JPRN-jRCT2031210616Kazuoki Kondou15
已完成
1 期
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy SubjectsHealthy VolunteersNCT03905291Medy-Tox25
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesAcute Traumatic Cervical Spinal Cord Injury, HTLV-1-Associated Myelopathy (HAM)JPRN-jRCT2031220182Kondo Kazuoki10